| Alnylam Pharmaceuticals, Inc. | $40.3b | $286.50 | 0.0% | 187 | |
| Ionis Pharmaceuticals, Inc. Common Stock | $12.6b | $78.07 | 0.0% | 69 | |
| Arrowhead Research Corporation | $11.0b | $79.54 | 0.0% | 5.0K | |
| Wave Life Sciences Ltd. Ordinary Shares | $1.3b | $5.79 | 0.0% | 2.4K | |
| CAMP4 Therapeutics Corporation Common Stock | $228.0m | $3.98 | 0.0% | 2 | |
| Atrium Therapeutics, Inc. Common Stock | $222.4m | $12.73 | 0.0% | 22 | |
| Cartesian Therapeutics, Inc. Common Stock | $221.5m | $8.88 | 0.0% | 3 | |
| ProQR Therapeutics N.V. Ordinary Shares | $166.5m | $1.51 | 0.0% | 5.7K | |
| Exicure, Inc. Common Stock | $20.3m | $2.61 | 0.0% | 12.5K | |
| Phio Pharmaceuticals Corp. Common Stock | $12.9m | $0.99 | 0.0% | 4.7K |